News & AnalysisCarisma Therapeutics nabs $59m Series BCarisma Therapeutics Inc., a biopharmaceutical company, has raised $59 million in Series B funding.ByIris Dorbian1 March 2021•1 min readJavaScript is required to read this article. Please enable it in your browser and reload the page.DealsHealthcareBriefs